BMB-101 in Absence Epilepsy and DEE

NCT06401538 | Recruiting Phase 2

• 1 other identifier: BMB-101-103
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 5

Brief Summary

The study is a pilot, open-label, study to test whether BMB-101 is safe and effective in reducing the frequency of seizures in subjects with Absence Epilepsy including Epilepsy with Eyelid Myoclonia (also called Jeavons Syndrome) as well as Developmental Epileptic Encephalopathies such as Dravet and Lennox Gastaut. The study will last up to 6 months. There will be a 1 month screening period, then up to 3 months on open-label BMB-101 including titration and tapering/washout periods, and then a 1 month follow-up period. There will be 6 clinic visits.

Conditions

Absence Epilepsy; Jeavons Syndrome; Dravet Syndrome; Lennox Gastaut Syndrome

Outcome Measures

Primary Outcomes (2)

• Change from baseline in seizure frequency in DEE subjects

  Seizure diary

  10 weeks

• Change from baseline in the number of generalized spike-wave discharges (GSWD) on the 24 hr EEG in Absence subjects.

  24 hour EEG

  6 weeks

Secondary Outcomes (1)

• Change from baseline in quality of life

  6-10 weeks

Study Arms (1)

BMB-101

EXPERIMENTAL

BMB-101 10 mg/ml liquid

Drug: BMB-101

Interventions

BMB-101 DRUG

BMB-101 liquid administered orally twice a day for 3 months

BMB-101

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects must have a diagnosis of Absence Epilepsy with or without eyelid myoclonia (Jeavons Syndrome) or a diagnosis of Developmental and Epileptic Encephalopathy (DEE) such as Dravet syndrome or Lennox-Gastaut syndrome or other DEE.
• Subjects with Absence must experience at least 4 episodes of 3-4/second SWD lasting at least 3 seconds each in a 24 hour EEG during the baseline period. Those with DEE must have a typical EEG pattern for DEE on routine EEG and experience at least 4 seizures during the 4 week baseline period prior to BMB-101 administration.
• Subjects can be male or female ages 18-65 inclusive at time of baseline.
• Subject must have tried at least one anti-seizure medication at a recommended dose and duration and must be on a stable dose on their current anti-seizure medications for at least 4 weeks prior to baseline and remain stable throughout the study.
• Subjectis willing and able to be compliant with diary completion, visit schedule, and study drug accountability.
• Female subjects of childbearing potential must have a negative urine pregnancy test at baseline. Subjects of childbearing or child-fathering potential must be willing to use medically acceptable forms of birth control, which includes abstinence, while in this study and for 90 days after the last dose of study drug.

You may not qualify if:

• Subject has current or past history of cardiovascular or cerebrovascular disease, such as cardiac valvulopathy, pulmonary hypertension, myocardial infarction or stroke, or clinically significant structural cardiac abnormality.
• Subject has moderate or severe hepatic impairment. Asymptomatic subjects with mild hepatic impairment (elevated liver enzymes \< 3x upper limit of normal (ULN) and/or elevated bilirubin \<2x ULN) may be entered into the study after review and approval by the Medical Monitor in conjunction with the sponsor, in consideration of comorbidities and concomitant medications.
• Subject has severe renal impairment (estimated glomerular filtration rate \<30mL/min/1.73m2)
• Clinically significant ECG abnormality such as QTcF \>450 msec (males) or \>470 msec (females)
• Subject is receiving concomitant therapy with: fenfluramine, lorcaserin, monoamine-oxidase inhibitors, SSRIs, SNRIs, tricyclic antidepressants or other serotonergic agonists or antagonists (antipsychotics).
• Subject is currently receiving an investigational medicinal product.
• Subject has participated in another clinical trial within the past 30 days (calculated from that study's last scheduled visit). Participation in non-treatment trials will be reviewed by the medical monitor.
• Subject has a history of drug or alcohol abuse within the last 12 months or a positive urine drug screen (with the exception of cannabinoids).
• A current C-SSRS score of 4 or 5 at baseline or history of suicide attempt at any time during the past year
• Subject has a clinically significant condition or has had clinically relevant symptoms or a clinically significant illness in the 4 weeks prior to the Baseline Visit, other than epilepsy, that would negatively impact study participation, collection of study data, or pose a risk to the subject.

Sponsors & Collaborators

• Bright Minds Biosciences Pty Ltd: lead

Study Sites (5)

The Prince of Wales Hospital

Randwick, New South Wales, 2031, Australia

RECRUITING

Royal Brisbane and Womans Hospital

Herston, Queensland, 4029, Australia

RECRUITING

St Vincent's Hospital Melbourne

Fitzroy, Victoria, 3065, Australia

RECRUITING

Austin Health

Heidelberg, Victoria, 3084, Australia

RECRUITING

Alfred Health

Melbourne, Victoria, 3004, Australia

RECRUITING

MeSH Terms

Conditions

Epilepsy, Absence; Epilepsies, Myoclonic; Lennox Gastaut Syndrome

Condition Hierarchy (Ancestors)

Epilepsy, Generalized; Epilepsy; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Epileptic Syndromes; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Officials

• Terence O'Brien, MD

  The Alfred

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Rachelle Kirk-Burnnand

CONTACT

+61 439615368; rachelle@basebio.com.au

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 2, 2024
• First Posted: May 6, 2024
• Study Start: December 5, 2024
• Primary Completion: September 15, 2025
• Study Completion: November 30, 2025
• Last Updated: August 12, 2025

Record last verified: 2025-08

Data Sharing

• IPD Sharing: Will not share

Locations

AU (5)